Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 218

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 218
---
ions) Pay vs. Performance: Total Shareholder Return $69.1 $(40.1) $(2.2) $(5.2) $6.1 $(0.4) $2.3 $2.6 $145.0 $76.8 $62.4 $31.0 $115.6 $67.5 $49.1 93.8 PEO CAP Non-PEO CAP ARWR TSR Peer Group TSR 09/30/21 09/30/22 09/30/23 09/30/24 $(20.0) $— $20.0 $40.0 $60.0 $80.0 $100.0 $120.0 $140.0 $160.0 $180.0 $200.0 $(29.0) $— $29.0 $58.0 $87.0 $116.0 $145.0 Table of Contents 2025 PROXY STATEMENT Executive Compensation 55

Compensation Actually Paid and Net Loss N et L os s ($ T ho us an ds ) C A P ($ M illions) Pay vs. Performance: Net Loss $69.1 $(40.1) $(2.2) $(5.2) $6.1 $(0.4) $2.3 $2.6 $(140,848) $(176,063) $(205,275) $(599,493) PEO CAP Non-PEO CAP Net Loss 09/30/21 09/30/22 09/30/23 09/30/24 $(600,000) $(500,000) $(400,000) $(300,000) $(200,000) $(100,000) $(75.0) $(50.0) $(25.0) $— $25.0 $50.0 $75.0 Table of Contents 2025 PROXY STATEMENT 56

Financial Performance Measures As described in greater detail in the Compensation Discussion and Analysis section, the Company’s executive compensation program reflects a variable pay-for- performance philosophy. The metrics that the Company uses for both our long-term and short-term incentive awards are selected based on an objective of incentivizing our NEOs to increase the value of our enterprise for our shareholders. The Company does not currently use any financial performance measures to link executive compensation actually paid to our performance. However, the most important performance measures used by the Company to link executive compensation actually paid to the Company